TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05535517

Intervention type: OTHER
Intervention: CeraVe SA Smoothing Cream
Description: The CeraVe Salicylic Acid (SA) Smoothing Cream contains salicylic acid as well as hydrating hyaluronic acid and three essential ceramides.

Intervention type: OTHER
Intervention: Propaira 20% Lactic Acid Exfoliating Lotion
Description: For smoothing rough skin.

Intervention type: OTHER
Intervention: Propaira 30% Urea Exfoliating Emollient
Description: 30% Urea, 7% Glycerin to smoothen rough skin.

Intervention type: OTHER
Intervention: KPAI
Description: The proposed score, Keratosis Pilaris Area Index (KPAI), is a 5-point IGA score (0-4) of five main body areas: face, upper limbs, lower limbs, trunk, and buttocks, for a maximum of 20 in two main categories, activity (erythema, skin roughness and papulation) and damage (pigmentation and scarring). The final score will be a maximum of 100.

Intervention type: OTHER
Intervention: KPAI
Description: The proposed score, Keratosis Pilaris Area Index (KPAI), is a 5-point IGA score (0-4) of five main body areas: face, upper limbs, lower limbs, trunk, and buttocks, for a maximum of 20 in two main categories, activity (erythema, skin roughness and papulation) and damage (pigmentation and scarring). The final score will be a maximum of 100.

Intervention type: OTHER
Intervention: KPAI
Description: The proposed score, Keratosis Pilaris Area Index (KPAI), is a 5-point IGA score (0-4) of five main body areas: face, upper limbs, lower limbs, trunk, and buttocks, for a maximum of 20 in two main categories, activity (erythema, skin roughness and papulation) and damage (pigmentation and scarring). The final score will be a maximum of 100.

Intervention type: OTHER
Intervention: KPAI
Description: The proposed score, Keratosis Pilaris Area Index (KPAI), is a 5-point IGA score (0-4) of five main body areas: face, upper limbs, lower limbs, trunk, and buttocks, for a maximum of 20 in two main categories, activity (erythema, skin roughness and papulation) and damage (pigmentation and scarring). The final score will be a maximum of 100.

Intervention type: OTHER
Intervention: KP-IGA
Description: A standard 5-point IGA score (0-4) defined specifically for KP
Study: NCT05809869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg intravenous infusion on week 1, 5, 9, 13, 17, 21 and 25 for a total of 7 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab 300mg intravenous infusion on week 1 only.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium-90 radioembolisation
Description: Yttrium-90 radioembolisation on week 2 only.
Study: NCT06217705

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Project Calm
Description: Project Calm is a \~30-minute self-guided digital intervention designed to teach children and adolescents empirically supported emotion regulation skills to facilitate self-calming when faced with intense negative emotions. Project Calm uses vignettes, interactive activities, and engaging graphics to teach youth calming skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Calm
Description: Project Calm is a \~30-minute self-guided digital intervention designed to teach children and adolescents empirically supported emotion regulation skills to facilitate self-calming when faced with intense negative emotions. Project Calm uses vignettes, interactive activities, and engaging graphics to teach youth calming skills.
Study: NCT05535517

Intervention type: OTHER
Intervention: KP-IGA
Description: A standard 5-point IGA score (0-4) defined specifically for KP

Intervention type: OTHER
Intervention: KP-IGA
Description: A standard 5-point IGA score (0-4) defined specifically for KP

Intervention type: OTHER
Intervention: KP-IGA
Description: A standard 5-point IGA score (0-4) defined specifically for KP
Study: NCT05478005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Description: Patients who receive a femoral nerve block during surgery, fill out a questionnaire and undergo a muscle strength test before surgery, undergo functional tests, a muscle strength test and are asked about pain intensity after surgery.
Study: NCT04853082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Limonene capsule
Description: All the recruiters will be given treatment under the guidance of basic diet. Basic dietary guidelines include high-quality protein and fresh green leafy vegetables. It need to controlled sugar, various sweets and high-calorie foods, frying and other foods with high oil content and foods with high cholesterol content. Limonene capsules group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo control group and limonene capsule administration group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the treatment group and the placebo control group at a ratio of 1:1. The drug was administered for 12 weeks, 3 times a day, 5 capsules each time.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Limonene capsules(Placebo)
Description: Limonene capsules(Placebo)
Study: NCT05733169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frequency lowering intervention
Description: Modified parametrization of the current frequency lowering parametrization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frequency lowering reference
Description: Current frequency lowering parametrization
Study: NCT05478005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular block
Description: Patients who receive an intra-articular block at the time of surgery, fill out a questionnaire and undergo a muscle strength test before surgery, undergo functional tests, a muscle strength test and are asked about pain intensity after surgery.
Study: NCT04656951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab added to induction regimen of bortezomib, cyclophosphamide and dexamethasone (VCD), to bortezomib and dexamethasone during maintenance and to lenalidomide and dexamethasone at progression/relapse.
Study: NCT06092645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surufatinib plus cadonilimab
Description: Surufatinib: 250mg , po,qd, d1-d21, every 3 weeks for a treatment cycle. Cadonilimab: 10mg/kg, iv, d1, every 3 weeks for a treatment cycle
Study: NCT06223828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 10mg/kg/dose (max dose 500mg) once daily for 3 days
Study: NCT05015881

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketone Ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
Description: Drink a single dose of ketone ester 1.9 kcal/kg

Intervention type: DRUG
Group type: OTHER
Intervention: FDG
Description: Echocardiogram, and 2-Deoxy-2-\[18F\] fluoro-D-glucose (FDG) PET scan.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FDG
Description: Echocardiogram, and 2-Deoxy-2-\[18F\] fluoro-D-glucose (FDG) PET scan.
Study: NCT04965649

Intervention type: GENETIC
Intervention: Phenotyping of total and innate CD8+T cells by flow cytometry
Description: Blood samples from patients in the active file of the Clinical Cytology and Cytogenetics Laboratory at Nîmes University Hospital will be analyzed (diagnosis already known). Samples will be representative of the different stages of the pathology.~For patients with a confirmed diagnosis of Chronic Myeloid Leukemia and Philadelphia+ Acute Lymphoblastic Leukemia), the remaining whole blood sample taken as part of the usual management will be sent for phenotyping of CD8+ TL (total and innate) by flow cytometry. Phenotyping will be performed on samples pooled at the end of the recruitment period.

Intervention type: GENETIC
Intervention: Phenotyping of total and innate CD8+T cells by flow cytometry
Description: Blood samples from patients in the active file of the Clinical Cytology and Cytogenetics Laboratory at Nîmes University Hospital will be analyzed (diagnosis already known). Samples will be representative of the different stages of the pathology.~For patients with a confirmed diagnosis of Chronic Myeloid Leukemia and Philadelphia+ Acute Lymphoblastic Leukemia), the remaining whole blood sample taken as part of the usual management will be sent for phenotyping of CD8+ TL (total and innate) by flow cytometry. Phenotyping will be performed on samples pooled at the end of the recruitment period.
Study: NCT06180811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Women's Health Delaware Food Farmacy
Description: Participants will receive medically tailored groceries (10 meals per person in the household per week from enrollment to 4 weeks after delivery) high in micronutrients that are delivered to their homes weekly. They will also interact weekly with their assigned Community Health Worker to address social needs and patient-centered goals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Standard of Care
Description: Participants will receive the usual standard of care.
Study: NCT05948293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Machine learning model called IDoser
Description: Patients in the intervention arm will be prescribed the first dose of FSH by IDoser, that will take into account the age of the patient, BMI, AFC and AMH. These data will be retrieved from the patient's clinical file after their first visit to the clinic, after providing the patient with informed consent documentation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard clinical practice
Description: Patients in the control group will be prescribed their first dose of FSH by the clinician according to standard clinical practice.
Study: NCT05868343

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Center-based Cardiac Rehabilitation Intervention
Description: The center-based cardiac rehabilitation program is 12 weeks in length. Participants will travel to the center twice a week for the duration of the program. Participants receive an individualized exercise program to be completed at the center according to Canadian recommendations. Twelve pre-recorded educational vignettes on various health topics and two group educational sessions on nutrition are offered to participants in person during the first twelve sessions at the center. In addition, at the beginning of the CR program, participants watch a motivational vignette from one of our patient partners about the importance and benefits of following the CR program. Depending on the needs of each participant, they may be referred to various external clinics within the Vitalité network, such as the Nutrition Service.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid Cardiac Rehabilitation Intervention
Description: The center-based cardiac rehabilitation program is 12 weeks in length. For the first six weeks, participants are required to attend the hospital twice a week. After that, there will be a gradual increase in home sessions for the remaining six weeks. When a patient has a home session, health professionals follow up with a phone call.Twelve pre-recorded educational vignettes on various health topics and two group educational sessions on nutrition are offered to participants in person during the first twelve sessions at the center. In addition, at the beginning of the CR program, participants watch a motivational vignette from one of our patient partners about the importance and benefits of following the CR program. Depending on the needs of each participant, they may be referred to various external clinics within the Vitalité network, such as the Nutrition Service.
Study: NCT05192382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paltusotine
Description: Paltusotine, tablets, once daily by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, tablets, once daily by mouth
Study: NCT05351385

Intervention type: PROCEDURE
Intervention: Hematolgy and Chemistry analysis
Description: Samples will be collected at Day 0, Day 5, Day 10 and Day 15

Intervention type: PROCEDURE
Intervention: Real Time PCR
Description: Samples will be collected at Day 0, Day 5, Day 10 and Day 15

Intervention type: PROCEDURE
Intervention: PROS assay COVID+
Description: Samples will be collected at Day 0, Day 5, Day 10 and Day 15

Intervention type: PROCEDURE
Intervention: Sflt1 assay COVID+
Description: Samples will be collected at Day 0 and Day 10

Intervention type: PROCEDURE
Intervention: PROS assay CONTROL
Description: Samples will be collected at Day 0 (+5)

Intervention type: PROCEDURE
Intervention: Sflt1 assay CONTROL
Description: Samples will be collected at Day 0 (+5)
Study: NCT04621890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LOAN2DOSE and COIN2DOSE
Description: This is a behavioral economics intervention designed to help improve meal time bolusing behaviors in youth with type 1 diabetes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LOAN2DOSE and COIN2DOSE
Description: This is a behavioral economics intervention designed to help improve meal time bolusing behaviors in youth with type 1 diabetes.
Study: NCT06279416

Intervention type: PROCEDURE
Intervention: fiberoptic intubation
Description: awake nasal fiberoptic intubation

Intervention type: PROCEDURE
Intervention: laryngeal mask airway-mediated aintree catheter
Description: awake intubation with laryngeal mask airway-mediated aintree catheter

Intervention type: PROCEDURE
Intervention: videolaryngoscopy
Description: awake intubation with videolaryngoscopy
Study: NCT05485428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: 12-weeks of high intensity interval exercise, 30 minutes thrice weekly
Study: NCT06526897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Computed Tomography
Description: Undergo chest CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Computed Tomography
Description: Undergo chest CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Radiography
Description: Undergo CXR

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05557578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with GEMOX (GOT) regimen
Description: Tislelizumab 200mg on day 1；Gemcitabine 1000mg/m2 on day 1、8；Oxaliplatin 135mg/m2 on day 1；cycle 3 weeks
Study: NCT04719897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIRST: Repairing Thoughts
Description: This intervention uses the Repairing Thoughts cognitive restructuring module of the FIRST (Feeling Calm, Increasing Motivation, Repairing Thoughts, Solving Problems, Trying the Opposite) cognitive behavioral therapy protocol. This psychotherapy module teaches adolescents that thoughts are linked to feelings and behaviors, and that thoughts are often guesses to interpreting the world around us. Adolescents are taught to notice their thoughts in real-time and evaluate the evidence that supports or contradicts the thoughts and interpretation. Adolescents are then taught strategies to re-interpret thoughts in a more realistic manner and notice changes in emotional and behavioral responses. Clinicians are provided with examples to enhance learning, and between-session practice is assigned as homework.
Study: NCT04922398

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma
Description: blood will be withdrawn from the patient then separation of the platelet rich layer and then injection in the ovary

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.9% normal saline will be injected in each ovary
Study: NCT06355531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FNP-223
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study: NCT06395597

Intervention type: DIAGNOSTIC_TEST
Intervention: Nine Hole Peg Test
Description: 3 attempts of each subtest of the Nine Hole Peg Test performed according to the Czech Extended Version of Manual for the Nine Hole Peg Test; questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: Nine Hole Peg Test
Description: 3 attempts of each subtest of the Nine Hole Peg Test performed according to the Czech Extended Version of Manual for the Nine Hole Peg Test; questionnaire
Study: NCT06059196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ARCHES (Addressing Reproductive Coercion in Health Settings)
Description: ARCHES (Addressing Reproductive Coercion in Health Settings) includes training existing contraceptive providers to (1) provide contraceptive clients with education on reproductive coercion and methods/ways to use contraceptive methods covertly if desired, (2) provide screening for reproductive coercion and intimate partner violence, (3) provide a referral to specialized services for those disclosing intimate partner violence, (4) and offer a palm-sized mini-booklet with educational information on reproductive coercion and intimate partner violence. A mobile application was developed to guide contraceptive providers through the counselling protocol.
Study: NCT06270030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNZ101 (Aceclidine /Brimonidine) ophthalmic solution
Description: Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNZ100 (Aceclidine) ophthalmic solution
Description: Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle) ophthalmic solution
Description: Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
Study: NCT04948307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OXD01 digital therapy
Description: OXD01 digital therapy, 1-2 times per week 15-30 minutes each time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: sublingual buprenorphine/naloxone Medication-assisted treatment, the current standard for opioid addiction; the use of medications in combination with counseling

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: sublingual buprenorphine/naloxone Medication-assisted treatment, the current standard for opioid addiction; the use of medications in combination with counseling
Study: NCT05704218

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sample
Description: the patient will have a blood sample in order to perform serology tests
Study: NCT05256732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 fasted
Description: AT-527 administered twice daily (BID) for 5 days fasted

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator fasted
Description: Matching placebo administered twice daily (BID) for 5 days fasted
Study: NCT06059196

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BCS+ (Balanced Counseling Strategy Plus)
Description: BCS+ (Balanced Counseling Strategy Plus) is a contraceptive counseling protocol that contraceptive providers use to help clients identify suitable contraceptive methods based on their preferences and previous contraceptive experiences. The BCS+ also includes systematic screening for other health services such as HIV/STI, cervical cancer, and breast cancer. The BCS+ was adopted by the Kenya MOH as the standard contraceptive counseling protocol in the country.
Study: NCT05256732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 fed
Description: AT-527 administered twice daily (BID) for 5 days fed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator fed
Description: Matching placebo administered twice daily (BID) for 5 days fed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527
Description: AT-527 administered twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 single dose
Description: AT-527 single dose fasted/fed cross-over
Study: NCT06059196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCS+ (Balanced Counseling Strategy Plus)
Description: BCS+ (Balanced Counseling Strategy Plus) is a contraceptive counseling protocol that contraceptive providers use to help clients identify suitable contraceptive methods based on their preferences and previous contraceptive experiences. The BCS+ also includes systematic screening for other health services such as HIV/STI, cervical cancer, and breast cancer. The BCS+ was adopted by the Kenya MOH as the standard contraceptive counseling protocol in the country.
Study: NCT04979442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAIN-32
Description: 260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trabectedin
Description: 1.5 mg/m2 body surface area as a 24-hour IV infusion, every 3 weeks
Study: NCT06324214

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Urolithin A (Mitopure)
Description: Compound belonging to the 'urolithin' class. First discovered over 40 years ago as a gut-derived metabolite in rats and subsequently in humans. A food and dietary ingredient, and more specifically, a post-biotic compound. Derived from ellagitannins, which are present in foods such as pomegranate, berries, and walnuts. An 'inducer' of mitophagy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo.
Study: NCT05767255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec + liraglutide
Description: The association of insulin degludec with liraglutide in the same device (IDegLira) is a potent and safe drug that reduces the risk of hypoglycemia.
Study: NCT04855760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL-1017
Description: REL-1017 tablet
Study: NCT06424613

Intervention type: DRUG
Intervention: Lithium Carbonate
Description: Participants must have been prescribed lithium for the past year and demonstrate at least 80% adherence to their lithium medication regimen during the first six months of the study period.

Intervention type: DRUG
Intervention: Non-lithium medication
Description: No history of lithium use within the past year